{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:15:39Z","timestamp":1786979739334,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"UCB Pharma Italy","award":["PROTOCOL RWE0988"],"award-info":[{"award-number":["PROTOCOL RWE0988"]}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["PROTOCOL RWE0988"],"award-info":[{"award-number":["PROTOCOL RWE0988"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00198-025-07722-8","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:36:54Z","timestamp":1760348214000},"page":"2459-2469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0755","authenticated-orcid":false,"given":"Giovanni","family":"Adami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bartezaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Piccinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pollastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mastropaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Fornari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"7722_CR1","doi-asserted-by":"publisher","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O et al\u00a0(2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344.https:\/\/doi.org\/10.1007\/s00198-018-4704-5","DOI":"10.1007\/s00198-018-4704-5"},{"issue":"16","key":"7722_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"15","key":"7722_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"1","key":"7722_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","volume":"33","author":"S Singh","year":"2022","unstructured":"Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J et al (2022) A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis. Osteoporos Int 33(1):1\u201312. https:\/\/doi.org\/10.1007\/s00198-021-06095-y","journal-title":"Osteoporos Int"},{"key":"7722_CR5","unstructured":"Agenzia Italiana del Farmaco (AIFA). Nota 79. 11 February 2025]; Available from: https:\/\/www.aifa.gov.it\/en\/nota-79."},{"issue":"4","key":"7722_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A et al (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34(4):632\u2013642. https:\/\/doi.org\/10.1002\/jbmr.3641","journal-title":"J Bone Miner Res"},{"key":"7722_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/annrheumdis-2023-eular.461","volume":"82","author":"G Adami","year":"2023","unstructured":"Adami G, Bertelle D, Fassio A, Benini C, Gatti D, Viapiana O et al (2023) OP0242 proportion of patients reaching the bone mineral density (BMD) surrogate threshold effect (STE) with bisphosphonates, denosumab and teriparatide. Ann Rheum Dis 82:161\u2013162. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.461","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7722_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell R, Vittinghoff E, Lui LY, McCulloch CE, Pavo I, Chines A et al (2022) Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. J Bone Miner Res 37(1):29\u201335. https:\/\/doi.org\/10.1002\/jbmr.4433","journal-title":"J Bone Miner Res"},{"key":"7722_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101194","volume":"16","author":"R Chapurlat","year":"2022","unstructured":"Chapurlat R, Bergh J, Ralston S, Ferrari S, McClung M, Lorentzon M et al (2022) Proportion of Patients Who Reach the BMD Surrogate Threshold Effect on Romosozumab: a Post Hoc Analysis of the Randomised FRAME and ARCH Phase 3 Trials. Bone Reports 16:101194. https:\/\/doi.org\/10.1016\/j.bonr.2022.101194","journal-title":"Bone Reports"},{"key":"7722_CR10","volume-title":"Prevention and management of osteoporosis : report of a WHO scientific group","author":"AQ WHO.","year":"2003","unstructured":"AQ WHO., S.G.o.t. Prevention, M.o. Osteoporosis (2003) Prevention and management of osteoporosis\u202f: report of a WHO scientific group. World Health Organization, Geneva"},{"issue":"11","key":"7722_CR11","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s40618-023-02082-8","volume":"46","author":"G Adami","year":"2023","unstructured":"Adami G, Biffi A, Porcu G, Ronco R, Alvaro R, Bogini R et al (2023) A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS. J Endocrinol Invest 46(11):2287\u20132297. https:\/\/doi.org\/10.1007\/s40618-023-02082-8","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"7722_CR12","first-page":"561","volume":"28","author":"S Adami","year":"2010","unstructured":"Adami S, Bianchi G, Brandi ML, Di Munno O, Frediani B, Gatti D et al (2010) Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol 28(4):561\u2013570","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"7722_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-015-0009-2","volume":"97","author":"G Bonaccorsi","year":"2015","unstructured":"Bonaccorsi G, Fila E, Cervellati C, Romani A, Giganti M, Rossini M et al (2015) Assessment of fracture risk in a population of postmenopausal Italian women: a comparison of two different tools. Calcif Tissue Int 97(1):50\u201357. https:\/\/doi.org\/10.1007\/s00223-015-0009-2","journal-title":"Calcif Tissue Int"},{"key":"7722_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","volume":"498","author":"Y Nishizawa","year":"2019","unstructured":"Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M et al (2019) Executive summary of the Japan Osteoporosis Society guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2018 edition). Clin Chim Acta 498:101\u2013107. https:\/\/doi.org\/10.1016\/j.cca.2019.08.012","journal-title":"Clin Chim Acta"},{"issue":"3","key":"7722_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","volume":"93","author":"Y Benjamini","year":"2006","unstructured":"Benjamini Y, Krieger AM, Yekutieli D (2006) Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93(3):491\u2013507. https:\/\/doi.org\/10.1093\/biomet\/93.3.491","journal-title":"Biometrika"},{"issue":"8","key":"7722_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E et al (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437\u20131445. https:\/\/doi.org\/10.1002\/jbmr.4563","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7722_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.4457","volume":"37","author":"EF Eriksen","year":"2022","unstructured":"Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S et al (2022) Modeling-based bone formation after 2 months of Romosozumab treatment: results from the FRAME clinical trial. J Bone Miner Res 37(1):36\u201340. https:\/\/doi.org\/10.1002\/jbmr.4457","journal-title":"J Bone Miner Res"},{"issue":"6","key":"7722_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33(6):1243\u20131256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","journal-title":"Osteoporos Int"},{"key":"7722_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/art.43179","author":"G Adami","year":"2025","unstructured":"Adami G, Saag KG (2025) Expert perspective: how, when, and why to potentially stop antiresorptive drugs in osteoporosis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43179","journal-title":"Arthritis Rheumatol"},{"key":"7722_CR20","unstructured":"Cartwright C, Anastasopoulou C (2025) Hungry Bone Syndrome. [Updated 2025 Feb 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549880\/"},{"issue":"8","key":"7722_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33(8):1397\u20131406. https:\/\/doi.org\/10.1002\/jbmr.3452","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07722-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:31:01Z","timestamp":1764682261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07722-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7722"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07722-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the protocol RWE0988 approved by our local Ethics Committee, in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was collected for each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Patients provided consent for the publication of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Giovanni Adami has received advisory board honoraria, consultancy fees, and\/or speaker fees from Theramex, UCB, Lilly, Galapagos, Fresenius Kabi, Amgen, BMS, Abiogen, and Pfizer. Davide Gatti has received advisory board honoraria, consultancy fees, and\/or speaker fees from Abiogen, Celgene, Eli-Lilly, Neopharmed-Gentili, Pfizer, and UCB. Maurizio Rossini reports advisory board honoraria, consultancy fees, and\/or speaker fees from AbbVie, Eli-Lilly, Italfarmaco, Neopharmed-Gentili, Theramex, UCB, outside the submitted work. Ombretta Viapiana has received advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Eli-Lilly, UCB, Abbvie, MSD, and BMS. Angelo Fassio reports personal fees from Abiogen, Novartis, and Neopharmed. Marta Bartezaghi and Rachele Fornari are employees of UCB. Filippo Montanari, Anna Piccinelli1, Francesco Pollastri, Francesca Mastropaolo, Francesco Giorgio, Camilla Benini have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}